Banque Cantonale Vaudoise’s Heron Therapeutics HRTX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,000	Closed	-$4K	–	869
2024 Q2	$4K	Hold	1,000	–	–	﹤0.01%	964
2024 Q1	$3K	Hold	1,000	–	–	﹤0.01%	963
2023 Q4	$2K	Hold	1,000	–	–	﹤0.01%	995
2023 Q3	$1K	Hold	1,000	–	–	﹤0.01%	1172
2023 Q2	$1K	Hold	1,000	–	–	﹤0.01%	1165
2023 Q1	$2K	Hold	1,000	–	–	﹤0.01%	1165
2022 Q4	$3K	Hold	1,000	–	–	﹤0.01%	1159
2022 Q3	$4K	Sell	1,000 -2,000	-67%	-$7.83K	﹤0.01%	1193
2022 Q2	$9K	Hold	3,000	–	–	﹤0.01%	1191
2022 Q1	$17K	Hold	3,000	–	–	﹤0.01%	1165
2021 Q4	$27K	Hold	3,000	–	–	﹤0.01%	1158
2021 Q3	$32K	Hold	3,000	–	–	﹤0.01%	1106
2021 Q2	$47K	Hold	3,000	–	–	﹤0.01%	1050
2021 Q1	$48K	Buy	3,000 +1,000	+50%	+$17.8K	﹤0.01%	1004
2020 Q4	$42K	Buy	2,000 +1,400	+233%	+$24.3K	﹤0.01%	958
2020 Q3	$9K	Buy	+600	New	+$9.36K	﹤0.01%	1020

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Banque Cantonale Vaudoise's HRTX Position: Q3 2024 in Review

Banque Cantonale Vaudoise sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 1,000 shares — an estimated $4K sold.

Banque Cantonale Vaudoise first reported a position in HRTX in Q3 2020 and held it in 16 quarters. The position peaked at $48K in Q1 2021. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

Banque Cantonale Vaudoise reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
Banque Cantonale Vaudoise sold 1,000 Heron Therapeutics shares in Q3 2024, an estimated $4K.
Banque Cantonale Vaudoise first reported a position in Heron Therapeutics in Q3 2020 and held it in 16 quarters.
Banque Cantonale Vaudoise's Heron Therapeutics position peaked at $48K in Q1 2021.
173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2024, filed 8 Nov 2024.